Onconova Therapeutics, Inc.·4

Mar 14, 7:19 PM ET

Guerin Mark Patrick 4

4 · Onconova Therapeutics, Inc. · Filed Mar 14, 2023

Insider Transaction Report

Form 4
Period: 2023-03-13
Guerin Mark Patrick
Chief Accounting Officer
Transactions
  • Award

    Stock Option (right to purchase)

    2023-03-13+79,00079,000 total
    Exercise: $0.73Exp: 2033-03-13Common Stock (79,000 underlying)
  • Award

    Restricted Stock Units

    2023-03-13+26,00026,000 total
    Common Stock (26,000 underlying)
Footnotes (3)
  • [F1]These options vest over three years, one-third on the first anniversary of the date of grant and thereafter in 24 equal monthly installments over the following two years.
  • [F2]Each restricted stock unit is convertible into one share of common stock.
  • [F3]These restricted stock units vest over 3 years from the date of grant: 33% on the first anniversary; 33% on the second anniversary; and 34 % on the third anniversary

Documents

1 file
  • 4
    form4-03142023_110331.xmlPrimary